ANAparecida Tiemi Nagao-Dias

Aparecida Tiemi Nagao-Dias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aparecida Tiemi Nagao-Dias has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antioxidant and Anti-inflammatory Activities of Bauhinia ungulata L. (Fabaceae) on LPS-Stimulated RAW 264.7 Cells

    by Raphael Rodrigues, Juliana Yaochite, Milena Braga, Amanda Sousa, Greyce Sasahara, Said Fonseca, Thiago Vasconcelos Araujo, Gilvandete Pinheiro Santiago, Leoncio De Sousa, Jarbas Carvalho, et al.

    Objective: The present study aimed to investigate the antioxidant, immunomodulatory and antimicrobial activities of Bauhinia ungulata L. Method: A flavonoid-rich fraction was obtained from the Bauhinia ungulata L stem, called the ethyl acetate fraction of Bauhinia ungulata (FABU). The total antioxidant capacity of the FABU was determined through the phosphomolibdenium reduction method. For the evaluation of its antioxidant activity on a cell culture model, LPS-stimulated RAW 264.7 cells were treated with different concentrations of FABU and the reactive oxygen species (ROS), nitric oxide (NO), hydrogen peroxide (H 2 O 2) and thiobarbituric acid reactive substances (TBARS) production levels were measured. For the analysis of its immunomodulatory capacity, TNF-α, TGF-β and IL-10 levels were determined in the culture supernatant. In order to determinate the antimicrobial activity of FABU, antifungal and antibacterial susceptibility testing was performed against Candida albicans, methicillinsensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa strains. Result: The FABU demonstrated neither significant antimicrobial activity nor immunodulatory capacity; on the other hand, its potential antioxidant activity was demonstrated by the phosphomolibdenium reduction assay. Also, FABU treatment inhibited the ROS, NO, H 2 O 2 and TBARS levels in the supernatant of LPS-stimulated cells. Conclusion: A significant reduction in the amount of reactive oxygen and nitrogen species (RONS) was observed, in addition to lipid peroxidation inhibition. Our data suggest that the FABU is a natural antioxidant complex that may interfere in the cascade of cell damage caused by free radicals and a promising potential drug in chronic disease models in which immunopathogenicity involves high levels of RONS.


  • Polymorphism of IL10, IL4, CTLA4, and DAO Genes in Cross-Reactive Nonsteroidal Anti-inflammatory Drug Hypersensitivity

    by Luciana Mabel Ferreira Vasconcelos, Raphael de Oliveira Rodrigues, Andressa Almeida Albuquerque, Gabrielle Dantheias Barroso, Greyce Luri Sasahara, Janaira Fernandes Severo Ferreira, Eudiana Vale Francelino, Cynthia Chester Cardoso, Silvia Helena Barem Rabenhorst, Thereza Lúcia Prata de Almeida, et al.

    Our aim was to evaluate genetic polymorphism of molecules involved in immunoregulatory/allergic processes in patients who presented with cutaneous hypersensitivity caused by chemically unrelated nonsteroidal anti-inflammatory drugs. Polymorphisms at IL10 (-1082 G>A), IL4 (-589 C>T), CTLA4 (+49A>G), and DAO (+8956 C>G) genes were studied in 55 cases and 97 controls by the polymerase chain reaction-restriction fragment length polymorphism technique. With regard to the polymorphism at IL10 -1082, higher frequencies of the AG genotype (57% vs 39%) and G allele carriers (70% vs 48%) were found among the patients, indicating a risk effect (odds ratio [OR] = 2.56 and P = .01 for AG genotype and OR = 2.52; P = .01 for AG/GG). For the CTLA4 +49 A/G single-nucleotide polymorphism (SNP), AG genotype (31.0%) (P = .02) and G carrier (54.0%) (P = .05) frequencies were found to be significantly lower in the patient group compared with the control group (51.0% and 69.0%, respectively). The SNP DAO +8956 C>G was associated with a strong protective effect, with OR values of 0.83 for CG and 0.11 for GG genotype (P = .04 for the codominant model), suggesting an allele dose effect. The combination of IL10 and DAO SNPs in a multivariate model did not alter the OR values, suggesting independent effects for both SNPs. The results are striking. In conclusion, these results suggest that polymorphisms in regulatory targets of the immune response and in DAO gene could modulate an individual's susceptibility to nonsteroidal anti-inflammatory drug hypersensitivity reactions. Further studies will be necessary to complement our results.


  • Open Access

    Serum anti‐phenolic glycolipid—1 IgA correlates to IgM isotype in leprosy patients: a possible candidate for seroepidemiological surveys?

    by Alexandre C. de Macedo, Juliana A. Guimarães, Raphael O. Rodrigues, Thiago D. V. Araújo, Clodis M. Tavares, Paula B. Cabral, Maria Isabel de Moraes‐Pinto, Aparecida T. Nagao‐Dias

    Objective: The aim of this study was to compare serum anti‐phenolic glycolipid‐1 IgA, IgG, and IgM levels in leprosy patients and controls.Method: Analysis of anti‐PGL‐1 IgA, IgG, or IgM in serum samples from multibacillary (MB, n=32) and paucibacillary (PB, n=22) leprosy patients, and in non‐endemic controls (n=17), using an indirect enzyme‐linked immunosorbent assay.Results: A strong correlation between serum IgM and IgA isotypes was found (r=.745, P<.0001) in MB patients. A moderate correlation was found in all analyses in PB patients. A moderate agreement was found between anti‐PGL1 IgA and IgM tests. Based on the ROC curves, the cut‐off values were selected and the parameters of validation were calculated. Considering the clinical forms altogether, the diagnostic sensitivities were 50.0% for IgA, 22.2% for IgG, and 74.1% for IgM. The positive (VPP) and negative (VPN) predictive values were estimated for each isotype. For IgA, the VPP and VPN were, respectively, 100.0% (87.0%‐100.0%; 95% confidence interval) and 38.7% (24.4%‐54.5%); for IgG, 100% (87.0%‐100.0%) and 28.8% (17.8%‐42.1%), respectively; and for IgM, 95.2% (83.8%‐99.4%) and 51.7% (32.5%‐70.6%), respectively.Conclusion: Despite the limiting factors, anti‐PGL1 IgA correlates to IgM levels and it could be considered as a possible laboratorial tool to be also used, for instance, in serological follow‐up studies.


  • CD38+CD8+ and CD38+CD4+ T Cells and IFN Gamma (+874) Polymorphism Are Associated with a Poor Virological Outcome

    by Paulo Germano de Carvalho, Raphael de Oliveira Rodrigues, Silvia Fernandes Ribeiro da Silva, Ilana Farias Ribeiro, Herene Barros de Miranda Lucena, Lilian Roberta Costa Martins, Silvia Helena Rabenhorst, Érico Antônio Gomes de Arruda, Aparecida Tiemi Nagao-Dias

    The main objective of the work was to evaluate the use of CD38 on T lymphocytes, IFNγ (+874 A/T), and IL-10 (−1082 A/G) polymorphisms in HIV-infected patients under antiretroviral (ARV) therapy. Sixty-one patients were selected at the outpatient clinic for HIV infection at the Hospital São José de Doenças Infecciosas, Fortaleza, Ceará, Brazil. The patients were classified into two groups, according to viral load after one year of ARV therapy. In the aviremic group (group I), a reduction of 35.5% of CD38+CD4+ T cells was observed (p = 0.02) and 49.3% of CD38+CD8+ T cells (p = 0.001). In the viremic group (group II), a reduction of 37.2% of CD38+CD4+ T cells (p = 0.067), and 21.4% of CD38+CD8+ T cells (p = 0.60) occurred. No association was found between IL-10 (−1082) polymorphism and the type of response to ARV therapy. Regarding the gene polymorphism on IFNγ (+874 T/A), 73.34% of group I and 33.3% of group II presented the AA genotype. The relative risk of the individuals carrying AA genotype or the A allele and not being able to suppress the viral load level after one year of ARV therapy was 3.44 (1.25–9.45; p = 0.014) or 2.35 (1.05–5.26; p = 0.027), respectively. Our data suggested that an augmented frequency of activated CD38+CD8+ T cells as well as the presence of the A allele of IFNγ polymorphism could contribute to a reduced virological suppression in patients under antiretroviral therapy.


  • Open Access

    Authors' reply: Vitamins in the treatment of chronic Chagas disease: adjuvant antiparasitary or antioxidant therapy?

    by Mônica Coelho Andrade, Maria De Fátima Oliveira, Aparecida Tiemi Nagao-Dias, Ivo Castelo Branco Coêlho, Darlan Da Silva Cândido, Erlane Chaves Freitas, Helena Lutéscia Luna Coelho, Fernando Schemelzer Moraes Bezerra

  • Open Access

    In Vitro and In Vivo Leishmanicidal Activity ofAstronium fraxinifolium(Schott) andPlectranthus amboinicus(Lour.) Spreng againstLeishmania (Viannia) braziliensis

    by Silvio César Gomes de Lima, Maria Jania Teixeira, José Evaldo Gonçalves Lopes Júnior, Selene Maia de Morais, Alba Fabiola Torres, Milena Aguiar Braga, Raphael Oliveira Rodrigues, Gilvandete Maria Pinheiro Santiago, Alice Costa Martins, Aparecida Tiemi Nagao-Dias

    The aim of the present work was to evaluate antileishmanial activity ofAstronium fraxinifoliumandPlectranthus amboinicus. For the in vitro tests, essential oil ofP. amboinicus(OEPA) and ethanolic extracts fromA. fraxinifolium(EEAF) were incubated with 106 promastigotes ofL. (Viannia) braziliensis. The OEPA was able to reduce the parasite growth after 48 h; nonetheless, all the EEAFs could totally abolish the parasite growth. For the in vivo studies, BALB/c mice were infected subcutaneously (s.c.) with 107 L. braziliensispromastigotes. Treatment was done by administering OEPA intralesionally (i.l.) for 14 days. No difference was found in lesion thickness when those animals were compared with the untreated animals. Further, golden hamsters were infected s.c. with 106 L. braziliensispromastigotes. The first protocol of treatment consisted of ethanolic leaf extract fromA. fraxinifolium(ELEAF) administered i.l. for 4 days and a booster dose at the 7th day. The animals showed a significant reduction of lesion thickness in the 6th week, but it was not comparable to the animals treated with Glucantime. The second protocol consisted of 15 daily intralesional injections. The profiles of lesion thickness were similar to the standard treatment. In conclusion, in vivo studies showed a high efficacy when the infected animals were intralesionally treated with leaf ethanolic extract fromA. fraxinifolium.


  • Open Access

    Efficacy ofPlectranthus amboinicus(Lour.) Spreng in a Murine Model of Methicillin-ResistantStaphylococcus aureusSkin Abscesses

    by Francisco Fábio Martins de Oliveira, Alba Fabiola Torres, Thially Braga Gonçalves, Gilvandete Maria Pinheiro Santiago, Cibele Barreto Mano de Carvalho, Milena Braga Aguiar, Lilia Maria Carneiro Camara, Silvia Helena Rabenhorst, Alice Maria Costa Martins, José Telmo Valença Junior, et al.

    The present work aimed to evaluate the effectiveness ofPlectranthus amboinicus(Lour.) Spreng against MRSA clinical isolates. The in vitro antimicrobial activity of the hydroalcoholic extract (HE), the ethyl acetate (EA) fraction and its subfractions were determined by broth microdilution and bioautography against MRSA clinical isolates. The microdilution checkerboard method was used to assess in vitro drug combination studies. To induce abscess formation, bacterial suspensions were added to Citodex and inoculated subcutaneously into male Swiss mice. The treatment protocol consisted of 2 doses of HE, the EA fraction or vancomycin introduced intraperitoneally into mice 3 and 12 h after infection. The EA fraction and its subfractions presented the lowest minimal inhibitory concentrations (MIC, 0.25 to 0.5 mg/mL). The plant samples were bacteriostatic at 2x and 4x MIC and bactericidal at 100 mg/mL. The EA fraction presented synergism with vancomycin and an additive effect with ciprofloxacin. A significant reduction of abscess volume, bacterial cell counts in abscess slurries, and inflammatory scores was observed in the HE and EA fraction-treated groups. The samples were effective in treating the animals in a dose-dependent fashion. The present study proved the effectiveness ofP. amboinicusfractions against MRSA using in vitro and in vivo assays.


  • In Response

    by Dionne Bezerra Rolim, Luciano Pamplona de Góes Cavalcanti, Timothy J. J. Inglis, Aparecida Tiemi Nagao-Dias

  • Open Access

    Implementation of a penicillin allergy skin test

    by Aparecida Tiemi Nagao-Dias, Ana Carla Pereira, Michelly Freitas e Silva, Eugenie Desiree Rabelo Néri, José Wilson Accioly, Janete Elisa Soares Lima

    The penicillin allergy skin testing is the only accurate and reliable test for penicillin hypersensitivity mediated by IgE. It is useful for identifying patients with doubtful history of allergy. Positive test for major and minor determinants presents a positive predictive value of 50% and negative predictive value of 99%. In Brazil, the Ministry of Health suggests a protocol for in house made reagents, since they are not commercially available. As the referred protocol does not mention some important details about the test procedures, we propose in the present work to implement them, critically evaluating each step in order to allow the protocol establishment at any health service, with quality and safety.


  • Diagnosing immune-mediated reactions to drugs

    by A.T. Nagao-Dias, F.M. Teixeira, H.L.L. Coelho

    Drug allergy is a type B adverse drug reaction, which is unpredictable and difficult to prevent or manage. In patients who have a previous history of drug allergy it must be confirmed by laboratorial diagnosis. However, the diagnostic test remains a major problem in clinical practice. Skin testing is validated for some drugs, such as penicillin, but not for others. Provocation test is a confirmatory test but bears the risk of severe reactions. Lymphocyte transformation test is a reliable test but is considered as a research tool. This review addresses the most recent published literature regarding the techniques which have already been developed as well as the new tests that can be promising alternatives for diagnosis of drug allergy.